Home Digestive Disorders IBD: Ulcerative Colitis What’s Health Canada Saying about Biosimilars?

IBD: Ulcerative Colitis

What’s Health Canada Saying about Biosimilars?

Tags: ,

A biosimilar biologic drug, or biosimilar, is a drug demonstrated to be highly similar to a biologic drug that was already authorized for sale (known as the reference biologic drug).  Biosimilars are approved based on a thorough comparison to a reference drug and may enter the market after the expiry of reference drug patents and data protection. Watch this video to get more insight into what Health Canada is saying about biosimilars!

This video was made possible by an unrestricted educational grant by Pfizer Canada. 

Related Articles

Biosimilars for IBD: Making the Transition Webinar
Biosimilars for IBD: Making the Transition Webinar

Tags: ,

  On May 28th, Dr. McCurdy answered the following questions in a very informative webinar presentation on Biosimilars: What’s the difference between a reference biologic drug […]

Read More

Fecal Calprotectin: The Inside Story on Inflammation

Tags:

Read More

FAQs

Tags:

Am I going to get cancer because I have (Ulcerative Colitis) IBD?  People with IBD are at an increased risk of developing colon cancer. Having regular […]

Read More

What’s Health Canada Saying about Biosimilars?

https://www.youtube.com/watch?v=6DkzQFdyNuY
A biosimilar biologic drug, or biosimilar, is a drug demonstrated to be highly similar to a biologic drug that was already authorized for sale (known as the reference biologic drug).  Biosimilars are approved based on a thorough comparison to a reference drug and may enter the market after the expiry of reference drug patents and data protection. Watch this video to get more insight into what Health Canada is saying about biosimilars!